Antengene Corporation Limited will present new data from two clinical trials evaluating selinexor at the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The presentations will feature results from a Phase III study in relapsed/refractory multiple myeloma (RRMM) and a Phase I/II study in relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL).
Selinexor in Relapsed/Refractory Multiple Myeloma
The Phase III Bench study (Abstract #4748) evaluated the efficacy and safety of weekly selinexor, bortezomib, and dexamethasone (SVd) compared to twice-weekly bortezomib and dexamethasone (Vd) in Chinese patients with RRMM. This study addresses the need for more effective and tolerable regimens in this patient population, where disease relapse remains a significant challenge.
The primary analysis of the Bench study will be presented by Dr. Jin Lu from Peking University People's Hospital. The study's corresponding author is Dr. Jian Hou from Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine. The presentation is scheduled for Monday, December 9, 2024.
Selinexor in Relapsed/Refractory Extranodal NK/T-Cell Lymphoma
Another presentation (Abstract #4448) will highlight preliminary results from Arm C of the TOUCH study, a multicenter, single-arm, Phase I/II trial. This arm investigates selinexor in combination with tislelizumab in patients with R/R ENKTL. ENKTL is an aggressive lymphoma subtype with limited treatment options, making the evaluation of novel combinations crucial.
The preliminary results of the TOUCH study will be presented by Dr. Rong Tao from Fudan University Shanghai Cancer Center, with Dr. Huiqiang Huang from Sun Yat-Sen University Cancer Center serving as the corresponding author. This poster presentation is also scheduled for Monday, December 9, 2024.
About Selinexor
Selinexor (XPOVIO®) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. It functions by blocking the nuclear export protein XPO1, leading to the accumulation and activation of tumor suppressor proteins within the nucleus, and reducing the levels of oncogenic proteins in the cytoplasm. This mechanism of action allows selinexor to exert antitumor effects through multiple pathways, including inducing the intranuclear accumulation of tumor suppressor proteins, reducing the level of oncogenic proteins, and restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway.
Antengene is currently conducting multiple clinical studies of selinexor in mainland China for the treatment of relapsed/refractory hematologic malignancies and solid tumors. Selinexor has already been approved in multiple regions, including Mainland China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, and Australia.
